CURRICULUM VITAE

FORMATO EUROPEO PER IL CURRICULUM VITAE

INFORMAZIONI PERSONALI

Nome e Cognome	**Giuseppe Procopio**
Indirizzo posta elettronica	Giuseppe.procopio@istitutotumori.mi.it; programma.prostata@istitutotumori.mi.it
Incarico attuale	Direttore Struttura Semplice Dipartimentale Oncologia Medica Genito-Urinaria

ISTRUZIONE E FORMAZIONE

•Data	2023
• Nome e tipo di istituto di istruzione o formazione	Abilitazione Scientifica Nazionale - Ministero Università e della Ricerca (MUR)
• Qualifica conseguita	Abilitazione a Professore di I Fascia – Area 6/D3 Malattie del sangue, oncologia e reumatologia
• Data	1997
• Nome e tipo di istituto di istruzione o formazione	Università degli Studi di Messina
• Qualifica conseguita	Specializzazione in Oncologia Medica
• Data	1992
• Nome e tipo di istituto di istruzione o formazione	Università degli Studi di Messina
• Qualifica conseguita	Laurea in Medicina e Chirurgia

ESPERIENZA LAVORATIVA

• Date (da – a)	APRILE 2023 – AD OGGI
• Nome e indirizzo del datore di lavoro	Fondazione IRCCS Istituto Nazionale dei Tumori – Via G. Venezian 1, Milano
• Tipo di azienda o settore	Oncologia Medica
• Tipo di impiego	Responsabile Struttura Semplice Dipartimentale Oncologia Medica Genitourinaria
• Date (da – a)	NOVEMBRE 2022 – MARZO 2023
• Nome e indirizzo del datore di lavoro	Fondazione IRCCS Istituto Nazionale dei Tumori – Via G. Venezian 1, Milano

• Tipo di azienda o settore	Oncologia Medica
• Tipo di impiego	Responsabile Struttura Semplice Oncologia Medica Genitourinaria
• Date (da – a)	NOVEMBRE 2022 – AD OGGI
• Nome e indirizzo del datore di lavoro	Fondazione IRCCS Istituto Nazionale dei Tumori – Via G. Venezian 1, Milano
• Tipo di azienda o settore	Programma Prostata – Progetto Speciale Direzione Scientifica
• Tipo di impiego	Direttore
• Date (da – a)	MAGGIO - OTTOBRE 2022
• Nome e indirizzo del datore di lavoro	Ospedale di Cremona, ASST Cremona, Viale Concordia 1, Cremona
• Tipo di azienda o settore	Oncologia Medica
• Tipo di impiego	Direttore Struttura Complessa Oncologia Medica
• Date (da – a)	2013 –2022
• Nome e indirizzo del datore di lavoro	Fondazione IRCCS Istituto Nazionale dei Tumori – Via G. Venezian 1, Milano
• Tipo di azienda o settore	Oncologia Medica
• Tipo di impiego	Responsabile Struttura Semplice Oncologia Medica Genitourinaria
• Date (da – a)	2000 – 2013
• Nome e indirizzo del datore di lavoro	Fondazione IRCCS Istituto Nazionale dei Tumori – Via G. Venezian 1, Milano
• Tipo di azienda o settore	Oncologia Medica
• Tipo di impiego	Dirigente Medico
• Date (da – a)	1998-1999
• Nome e indirizzo del datore di lavoro	Fondazione IRCCS Istituto Nazionale dei Tumori – Via G. Venezian 1, Milano
• Tipo di azienda o settore	Oncologia Medica
• Tipo di impiego	Ricercatore Associato

ALTRO

ATTIVITA' SCIENTIFICA:

L'attività scientifica è rivolta prevalentemente alle neoplasie del tratto genitourinario.

È autore/coautore di **oltre 330 articoli** pubblicati su riviste indicizzate, di cui 151 negli ultimi 5 anni.

Il suo **H index è 46**, con un **numero di citazioni pari a 14,740** (Ultimo aggiornamento: 14/04/2025)

È Principal Investigator (fino al 30 aprile 2022) di nr **40 studi clinici**, attivati a partire dal 2014.

È Principal Investigator/Co-Investigator di **6 progetti di ricerca No Profit**, con una gestione di risorse economiche pari a 2.958.000 euro:

- Partecipante e Coordinatore Obiettivo 6 "Immunoterapie innovative per il carcinoma a cellule renali" nel progetto IMMUNOHUB, finanziato dal Ministero della Salute nell'ambito della "Traiettoria 4 "Biotecnologie, Bioinformatica e Sviluppo Farmaceutico- Linea di azione 4.1 Creazione di Hub delle Scienze della Vita", coordinato dall'Università di Pavia. ConvenzioneT4-CN-02
- Partecipante e Principal Investigator per l'Italia del progetto di ricerca Horizon Europe dal titolo "First line randomized study platform to optimize treatment in patients with metastatic renal cell carcinoma - CARE 1", coordinato dall'Insitute Gustave Rossy (Francia). Proposal number: 101104801, HORIZON-MISS-2022-CANCER-01 Research and Innovation actions supporting the implementation of the

Mission on Cancer, Topic: HORIZON-MISS-2022-CANCER-01-03, Type of Action: HORIZON-RIA. Grant Agreement in fase di sottoscrizione.

- Principal Investigator del progetto di ricerca multicentrico dal titolo "Multiomics approach for patients stratification and novel target identification in metastatic clear cell renal carcinoma", finanziato dall'Associazione Italiana per la Ricerca sul Cancro (AIRC) - Progetto IG 2021 ID 26108
- Partecipante del progetto di ricerca Horizon 2020 dal titolo "Knowledge At the Tip of Your fingers: Clinical Knowledge for Humanity - KATY" (https://katy-project.eu/), coordinato dall'Università degli Studi Tor Vergata, finanziato dalla European Commission, Grant Agreement (GA) No: 101017453, Call/Topic: AI for Genomics and Personalised Medicine - Type of action: Research and Innovation action
- Principal Investigator del progetto di ricerca dal titolo "Prospective translational study investigating predictors of outcome in metastatic renal cell carcinoma patients treated with Nivolumab (I-Rene trial)", finanziato dal Ministero della Salute nel Bando di Ricerca Finalizzata 2016 *(concluso)*
- Principal Investigator del progetto di ricerca dal titolo "Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery" finanziato dall'Associazione Italiana per la Ricerca sul cancro (AIRC) - Progetto IG 2014 Id.15792 *(concluso)*
- Coordinatore del progetto SATURNO "Study: multicenter, proSpective, non-interventional Italian registry of Advanced/meTastatic Urothelial caRciNOma" - Registro dei tumori uroteliali avanzati, promosso dalla Federation of Italian Cooperative Oncology Groups (FICOG).

PARTECIPAZIONE A SOCIETÀ SCIENTIFICHE

Incarichi in importanti società scientifiche nazionali e internazionali:

- Membro del Consiglio Direttivo dell'Associazione Italiana di Oncologia Medica (AIOM) con mandato consecutivo dal 2015 ad oggi.
- Presidente del Consiglio Direttivo della Federation of Italian Cooperative Oncology Groups (FICOG), società fondata nel 2015 che raggruppa numerosi gruppi cooperativi oncologici italiani, per sviluppare ed implementare la ricerca clinica in Italia ed a livello internazionale.
- Segretario scientifico, Membro del Consiglio Direttivo e Presidente di MEET-URO: Italian Netwotk for Research in Urologic-Oncology, associazione che ha lo scopo di riunire i cultori della Oncologica medica Urologica al fine di promuoverne il progresso nel campo clinico, sperimentale e socio-assistenziale, di favorire i rapporti tra gli specialisti di urologia oncologica, i medici di medicina generale e gli specialisti di altre discipline, di stabilire relazioni scientifiche con analoghe Associazioni italiane ed Internazionale. L'Associazione ha, inoltre, lo scopo di promuovere la ricerca sperimentale e clinica, la qualità delle cure oncologiche e la interdisciplinarietà.
- Membro del Comitato Etico per l'Assistenza e per la Ricerca dell'IRCCS San Raffaele di Milano, a cui afferiscono il Policlinico IRCCS di San Donato Milanese, l'Istituto Ortopedico Galeazzi IRCCS di Milano, il San Raffaele Turro di Milano e l'Istituto Clinico Sant'Ambrogio di Milano.
- Membro del Board per la progettazione, la revisione e la stesura dei Percorsi diagnostici e terapeutici assistenziali (PDTA) per le patologie oncologiche del rene e della prostata di INTMI
- Membro del Gruppo di lavoro dell'European Society of Medical Oncology (ESMO) per la stesura delle Linee Guida sulla diagnosi e il trattamento del carcinoma della prostata in fase localizzata o avanzata dal 2019 e sulla diagnosi e il trattamento del carcinoma del rene in fase localizzata o avanzata dal 2021
- Membro dell'European Association Urology (EAU) per il Gruppo di Lavoro Linee Guida Rene;

- Coordinatore delle linee guida AIOM sulla diagnosi ed il trattamento del tumore del rene
- Revisore delle linee guida AIOM sulla diagnosi ed il trattamento del tumore della prostata
- Socio di importanti società scientifiche quali ASCO, ESMO, AIOM.

PARTECIPAZIONE A CONGRESSI

Negli ultimi 5 anni (2019-2024) ha partecipato a oltre 550 Congressi nazionali e internazionali con il ruolo di Chair, Moderatore, Discussant, Relatore e Docente.

INCARICHI DI DOCENZA

Oltre a rivestire il ruolo di Professore a contratto presso la Scuola di Specializzazione in Oncologia Medica dell'Università degli Studi di Milano, è titolare dei seguenti incarichi:

- Professore a contratto per lo svolgimento di attività seminarile sul tema "Strategie future per il trattamento dei tumori urologici" nell'ambito della Scuola di Specialità in Oncologia Medica dell'Università degli Studi di Modena e Reggio Emilia (UNIMORE) – 2023
- Docenza presso la Humanitas University, Pieve Emanuele (Milano), nell'ambito del Master di II livello in Terapia con Radioligandi, anno accademico 2022/2023, in collaborazione con l'Università Cattolica del S. Cuore di Roma e l'Istituto Nazionale Tumori di Milano. 2022-23
- Docente presso la International School of Medical sciences al 54 Corso: Evolving knowledge in the management of solid tumors: from molecular characterization to new therapeutic options in adult and elderly people". Lezione dal titolo "Advanced prostate cancer treatment: state of art", organizzato dalla Ettore Majorana Foundation and Centre for scientific culture con l'Università degli Studi di Palermo, con il supporto del MIUR, del Ministero della Salute, della N.A.T.O. Scientific General Assembly Committee, dalla Regione Sicilia, dal Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO) e dall'AIOM. ERICE-TRAPANI-SICILY. 2017
- Docenza nell'ambito della 16° edizione del Master Universitario di II Livello "Manager di Dipartimenti Farmaceutici" dell'Università degli Studi di Camerino, in collaborazione con la Società Italiana di Farmacia Ospedaliera, la Società Italiana di Farmacologia, l'Area vasta n. 5 della ASUR Marche Ascoli Piceno - San Benedetto del Tronto e l'Azienda Socio Sanitaria Territoriale "Papa Giovanni XXIII", Bergamo 2017

ATTIVITÀ EDITORIALE

È Section Editor per la rivista Tumori Journal - Genitourinary section (IF 2,438).

È Guest Associate Editor per la rivista Frontiers in Oncology - Section: Genitourinary Oncology (IF 5.738).

È' membro dell'Editorial Board per la rivista Therapeutic Advances in Urology (IF 3.130).

È stato Associate Editor per la rivista Cancer Breaking News.

È Reviewer di riviste scientifiche tra le quali: Lancet Oncology, Annals of Oncology, British Journal of Cancer, European Journal of Cancer, Clinical Cancer Research, Cancer Treatment Review, Cancer Medicine, Critical Review Oncology Hematology.

VALUTAZIONI COLLEGIO TECNICO FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI (quinquennio)

DATA COLLEGIO TECNICO: 24 SETTEMBRE 2019

ESITO VALUTAZIONE: OTTIMO

RIFERITO A: INCARICO DI STRUTTURA SEMPLICE ONCOLOGIA MEDICA GENITO-URINARIA

Il sottocritto Giuseppe Procopio ai sensi e per gli effetti degli articoli 46 e 47 e consapevole delle sanzioni penali previste dall'articolo 76 del D.P. R. 28 dicembre 2000, n. 445 nelle ipotesi di falsità in atti e dichiarazioni mendaci, dichiara che le informazioni riportate nel presente curriculum vitae, redatto in formato europeo, corrispondono a verità.

Autorizzo al trattamento dei dati personali presenti nel Curriculum Vitae secondo l'art. 13 del D. Lgs. 196/2003 e l'art. 13 GDPR 679/16.

DATA: 14/04/2025

FIRMA:

Allegato 1: PUBBLICAZIONI

ALLEGATO a CV
Bibliografia Dr Giuseppe Procopio

1. Stellato, M. et al. Pathological Complete Response in Metastatic Renal Cell Carcinoma Patients Treated With Cabozantinib Plus Nivolumab. Case Series and Literature Review. Clin. Genitourin. Cancer 23, (2025).
2. Staehler, M. et al. A Prospective Non-interventional Real-World Study of cabozantinib in Pretreated Patients With Advanced Renal Cell Carcinoma Refractory to Vascular Endothelial Growth Factor-Targeted Therapy (CASSIOPE). Clin. Genitourin. Cancer 23, (2025).
3. Maiorano, B. A. et al. Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study. Clin. Genitourin. Cancer 23, (2025).
4. Clarke, N. W. et al. Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial. Eur Urol Oncol 8, 394–406 (2025).
5. Brunelli, C. et al. Patient Voices: Multimethod Study on the Feasibility of Implementing Electronic Patient-Reported Outcome Measures in a Comprehensive Cancer Center. JMIR Cancer 11, (2025).
6. Stellato, M. et al. Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27. Clin. Genitourin. Cancer 22, (2024).
7. Sepe, P. et al. A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study). Ther. Adv. Med. Oncol. 16, (2024).
8. Santoni, M. et al. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? Eur Urol Oncol 7, 102–111 (2024).
9. Rebuzzi, S. E. et al. International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma – Meet-URO 33 study (REGAL study). BMC Cancer 24, (2024).
10. Rametta, A. et al. Hot topics in genitourinary cancers: A multidisciplinary discussion on state-of-the-art and latest developments among international experts and patient advocacy. Tumori 110, 410–415 (2024).
11. Powles, T. et al. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆. Ann. Oncol. 35, 692–706 (2024).
12. Patrikidou, A. et al. Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study. Clin. Genitourin. Cancer 22, (2024).
13. Nasca, V. et al. Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial. Eur. J. Cancer 209, (2024).
14. Murianni, V. et al. Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study. Front. Oncol. 14, (2024).
15. Motzer, R. J. et al. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. J. Clin. Oncol. 42, 1222–1228 (2024).
16. Messina, C. et al. Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis

of meet-URO15 study. Cancer Immunol. Immunother. 73, (2024).

17. Massari, F. et al. Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study. Cancer Immunol. Immunother. 73, (2024).
18. Marvaso, G. et al. Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology. Lancet Oncol. 25, e193–e204 (2024).
19. Maiorano, B. A. et al. Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. JAMA Netw. Open 7, E241215 (2024).
20. Maiorano, B. A. et al. Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis. Targeted Oncol. 19, 1–11 (2024).
21. Iacovelli, R. et al. Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study. Eur. Urol. 86, 411–419 (2024).
22. Gross-Goupil, M. et al. Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence. Clin. Genitourin. Cancer 22, 84–97 (2024).
23. Giunta, E. F. et al. Pharmacological treatment landscape of non-metastatic hormone-sensitive prostate cancer: A narrative review on behalf of the meet-URO Group. Crit. Rev. Oncol. Hematol. 204, (2024).
24. Giudice, G. C. et al. Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the Kidney. Clin. Genitourin. Cancer 22, (2024).
25. Fotia, G. et al. Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS—Meet-URO 26 Study. Clin. Genitourin. Cancer 22, (2024).
26. El Zarif, T. et al. First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study. Eur. Urol. 86, 503–512 (2024).
27. Damassi, A. et al. Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9). Clin. Genitourin. Cancer 22, 126-133.e2 (2024).
28. Dalla Volta, A. et al. Whole-body Diffusion-weighted Magnetic Resonance Imaging for Assessment of the Bone Response Rate in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Enzalutamide. Eur. Urol. 86, 268–271 (2024).
29. Cursano, M. C. et al. Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies. ESMO Open 9, (2024).
30. Conteduca, V. et al. Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care. Prostate Cancer Prostatic Dis. (2024) doi:10.1038/s41391-024-00800-8.
31. Catto, J. W. F. et al. Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer. Ann. Oncol. 35, 98–106 (2024).
32. Catalano, M. et al. Impact of Metastatic Site in Favorable-Risk Renal Cell Carcinoma Receiving Sunitinib or Pazopanib. Clin. Genitourin. Cancer 22, 514-522.e1 (2024).
33. Albiges, L. et al. Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review. Cancer Treat. Rev. 122, (2024).
34. Vignani, F. et al. Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial. Eur. Urol. 83, 82–89 (2023).

35. Thulasi Seetha, S. et al. Stability of Multi-Parametric Prostate MRI Radiomic Features to Variations in Segmentation. J. Pers. Med. 13, (2023).
36. Stellato, M. et al. Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a). Int. J. Mol. Sci. 24, (2023).
37. Santoni, M. et al. Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study. Targeted Oncol. 18, 559–570 (2023).
38. Santoni, M. et al. Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1). Clin. Genitourin. Cancer 21, e309-e319.e1 (2023).
39. Saad, F. et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1094–1108 (2023).
40. **Procopio, G.** et al. A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03). Tumori 109, 129–137 (2023).
41. Porta, C. et al. Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations. Minerva Urol. Nephrol. 75, 460–470 (2023).
42. Pal, S. K. et al. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet 402, 185–195 (2023).
43. Nuzzo, P. V. et al. Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. Ther. Adv. Med. Oncol. 15, (2023).
44. Nuzzo, P. V. et al. Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. J. Transl. Med. 21, (2023).
45. Nicolai, N. et al. Retroperitoneal lymph-node dissection (RPLND) as upfront management in stage II germ-cell tumours: Evaluation of safety and efficacy. Tumori 109, 379–386 (2023).
46. Matsubara, N. et al. Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA. Clin. Cancer Res. 29, 92–99 (2023).
47. Internò, V. et al. An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study. ESMO Open 8, (2023).
48. Grünwald, V. et al. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. Eur Urol Oncol 6, 437–446 (2023).
49. Grünwald, V. et al. Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study. Onkourologiya 19, 32–43 (2023).
50. Gillessen, S. et al. Darolutamide Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer with Nonprogressive Disease after Taxane Treatment (SAKK 08/16). in J. Clin. Oncol. vol. 41 3608–3615 (Lippincott Williams and Wilkins, 2023).

51. Fotia, G. et al. Current Status of Predictive Biomarker Development in Metastatic Renal Cell Carcinoma. Curr. Oncol. Rep. 25, 671–677 (2023).
52. Fiala, O. et al. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study. Cancer Immunol. Immunother. 72, 3665–3682 (2023).
53. De Giorgi, U., Giunta, E. F., Verzoni, E. & Procopio, G. Adding PARP inhibitor to an androgen-receptor signaling inhibitor in metastatic prostate cancer: what are we missing? Ann. Oncol. 34, 729–731 (2023).
54. Catalano, M. et al. Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab. JAMA Netw. Open E2345185 (2023) doi:10.1001/jamanetworkopen.2023.45185.
55. Catalano, M. et al. Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat? Pharmacol. Ther. 249, (2023).
56. Caminiti, C. et al. Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®). Tumori 109, 324–334 (2023).
57. Buti, S. et al. BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients. Tumori 109, 418–423 (2023).
58. Buti, S. et al. Concomitant Drugs Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication. J. Immunother. 46, 22–26 (2023).
59. Berruti, A. et al. nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives. Cancer Treat. Rev. 115, (2023).
60. Bazzocchi, M. V. et al. The Role of CT Imaging in Characterization of Small Renal Masses. Diagn. 13, (2023).
61. Thiery-Vuillemin, A. et al. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. Lancet Oncol. 23, 393–405 (2022).
62. Sternberg, C. N. et al. Case report: Metastatic urothelial cancer with an exceptional response to immunotherapy and comprehensive understanding of the tumor and the tumor microenvironment. Front. Oncol. 12, (2022).
63. Russo, A. et al. Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. ESMO Open 7, (2022).
64. Roviello, G. et al. Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study. Cancer Med. 11, 3084–3092 (2022).
65. Roviello, G. et al. Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors. Front. Oncol. 12, (2022).
66. Roubaud, G. et al. Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. Eur. J. Cancer 170, 73–84 (2022).
67. Rebuzzi, S. E. et al. The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis. Front. Oncol. 12, (2022).
68. Rebuzzi, S. E. et al. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program. ESMO Open 7, (2022).
69. Rebuzzi, S. E. et al. The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study. J. Transl. Med. 20, (2022).
70. Rebuzzi, S. E. et al. Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second-

and third-line cabozantinib. Ther. Adv. Med. Oncol. 14, (2022).

71. **Procopio, G**. et al. Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study). JAMA Oncol. 8, 910–913 (2022).
72. **Procopio, G.** et al. Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study. ESMO Open 7, (2022).
73. Powles, T. et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 23, 1133–1144 (2022).
74. Pal, S. K. et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet 400, 1103–1116 (2022).
75. Ottini, A. et al. Biomarker-driven immunotherapy for precision medicine in prostate cancer. Personalized Med. 19, 51–66 (2022).
76. Orlacchio, A. et al. SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations—consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM). Radiol. Med. 127, 534–542 (2022).
77. Mennitto, A. et al. Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). Expert Rev. Anticancer Ther. 22, 115–121 (2022).
78. Masini, C. et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. Eur. Urol. 81, 274–282 (2022).
79. Iacovelli, R. et al. Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations. Cancer Treat. Rev. 105, (2022).
80. Iacovelli, R. et al. Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib. Clin. Genitourin. Cancer 20, 498.e1-498.e9 (2022).
81. Fuoco, V. et al. Update on radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effects. Tumori 108, 315–325 (2022).
82. Franza, A., Claps, M. & Procopio, G. PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls. Transl. Oncol. 15, (2022).
83. Del Re, M. et al. The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs. J. Transl. Med. 20, (2022).
84. Choueiri, T. K. et al. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy. J. Immunother. Cancer 10, (2022).
85. Catalano, M. et al. Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma. Biomedicines 10, (2022).
86. Brunelli, M. et al. MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. J. Clin. Pathol. 75, 39–44 (2022).
87. Brunelli, M. et al. Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. J. Pers. Med. 12, (2022).
88. Bottiglieri, A. et al. Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy. Cancer Manage. Res. 14, 3071–3081 (2022).

89. Basso, U. et al. Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study. Cancers 14, (2022).
90. Stellato, M. et al. Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b). Front. Oncol. 11, (2021).
91. Stellato, M. et al. Bone metastases from urothelial carcinoma. The dark side of the moon. J. Bone Oncol. 31, (2021).
92. Stellato, M. et al. Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators. J. Transl. Med. 19, (2021).
93. Sepe, P. et al. Characteristics and treatment challenges of non-clear cell renal cell carcinoma. Cancers 13, (2021).
94. Santoni, M. et al. Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. Targeted Oncol. 16, 625–632 (2021).
95. Santoni, M. et al. Body mass index in patients treated with cabozantinib for advanced renal cell carcinoma: A new prognostic factor? Diagn. 11, (2021).
96. Santini, D. et al. Clinical Outcomes of Metastatic Renal Carcinoma following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7). Am. J. Clin. Oncol. Cancer Clin. Trials 44, 121–125 (2021).
97. Santini, D. et al. Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE. J. Bone Oncol. 26, (2021).
98. Rinchai, D. et al. Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. Clin. Transl. Med. 11, (2021).
99. Rebuzzi, S. E. et al. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). Ther. Adv. Med. Oncol. 13, (2021).
100. Ratta, R. et al. Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma. Tumori 107, 542–549 (2021).
101. Powles, T. et al. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann. Oncol. 32, 1511–1519 (2021).
102. Motzer, R. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. New Engl. J. Med. 384, 1289–1300 (2021).
103. Mosca, A. et al. An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: The 'Pamerit' study. Jpn. J. Clin. Oncol. 51, 484–491 (2021).
104. Mennitto, A. et al. Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial. Expert Rev. Clin. Pharmacol. 14, 261–268 (2021).
105. Maruzzo, M. et al. Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14). Front. Oncol. 11, (2021).
106. Kartolo, A., Procopio, G. & Vera-Badillo, F. E. Management of Favorable-risk Advanced Renal Cell Carcinoma: Is Dual Therapy the Answer? Eu. Uro. Op. Sci 30, 44–46 (2021).
107. Guadalupi, V. et al. Second-line treatment in renal cell carcinoma: clinical experience and decision making. Ther. Adv. Urol. 13, (2021).
108. Gargiuli, C. et al. Integrative transcriptomic analysis reveals distinctive molecular traits and novel subtypes of collecting duct carcinoma. Cancers 13, (2021).
109. Franchina, V. et al. Patient associations and clinical oncology research: how much does a patient's voice really matter?

Expert Rev. Pharmacoecon. Outcomes Res. 21, 433–440 (2021).

110. de Velasco, G. et al. Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib. BJU Int. 128, 254–261 (2021).
111. Ciccarese, C. et al. Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis. Cancer Treat. Rev. 100, (2021).
112. Caminiti, C. et al. Effectiveness of a Psychosocial Care Quality Improvement Strategy to Address Quality of Life in Patients with Cancer: The HuCare2 Stepped-Wedge Cluster Randomized Trial. JAMA Netw. Open 4, (2021).
113. Bongiovanni, A. et al. First prospective data on breast cancer patients from the multicentre italian bone metastasis database. Sci. Rep. 11, (2021).
114. Bersanelli, M. et al. Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group). Immunother. 14, 107–114 (2021).
115. Bersanelli, M. et al. Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next? Eur. Urol. Oncol. 4, 274–281 (2021).
116. Bersanelli, M. et al. The right immune-modulation at the right time: Thymosin α1 for prevention of severe COVID-19 in cancer patients. Future Oncol. 17, 1097–1104 (2021).
117. Bersanelli, M. et al. GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. Ther. Adv. Urol. 13, (2021).
118. Bersanelli, M. et al. Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). Clin. Med. Insights: Oncol. 15, (2021).
119. Basso, U. et al. Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16). Oncology 99, 747–755 (2021).
120. Stellato, M. et al. The emerging role of PARP inhibitors in prostate cancer. Expert Rev. Anticancer Ther. (2020) doi:10.1080/14737140.2020.1797497.
121. Sepe, P., Mennitto, A., Corti, F. & Procopio, G. Immunotherapeutic targets and therapy for renal cell carcinoma. ImmunoTargets Ther. 9, 273–288 (2020).
122. Sepe, P. et al. Prospective translational study investigating molecular PrEdictors of resistance to first-line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study). Am. J. Clin. Oncol. Cancer Clin. Trials 43, 621–627 (2020).
123. Santoni, M. et al. Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors. Cancers 12, (2020).
124. Santini, D. et al. Bone health management in the continuum of prostate cancer disease: A review of the evidence with an expert panel opinion. ESMO Open 5, (2020).
125. Raimondi, A. et al. Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer. Front. Oncol. 10, (2020).
126. Raimondi, A. et al. Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori. Tumori 106, 406–412 (2020).
127. **Procopio, G.**, Nichetti, F. & Verzoni, E. Pembrolizumab plus axitinib: another step ahead in advanced renal cell carcinoma. Lancet Oncol. 21, 1538–1539 (2020).
128. **Procopio, G**. et al. Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study. Ther. Adv. Med. Oncol.

12, (2020).

129. Porta, C. et al. Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial. Tumori 106, 257–266 (2020).
130. Parker, C. et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann. Oncol. 31, 1119–1134 (2020).
131. Motzer, R. J. et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer 126, 4156–4167 (2020).
132. Mennitto, A. et al. Angiogenesis and immunity in renal carcinoma: Can we turn an unhappy relationship into a happy marriage? J. Clin. Med. 9, (2020).
133. Marandino, L. et al. The Shifting Landscape of Genitourinary Oncology During the COVID-19 Pandemic and how Italian Oncologists Reacted: Results from a National Survey. Eur. Urol. 78, e27–e35 (2020).
134. Iacovelli, R. et al. Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. Targeted Oncol. 15, 495–501 (2020).
135. Iacovelli, R. et al. Patients with sarcomatoid renal cell carcinoma – re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. Eur. J. Cancer 136, 195–203 (2020).
136. Fratino, L. et al. Coronavirus: Older Persons With Cancer in Italy in the COVID-19 Pandemic. Front. Oncol. 10, (2020).
137. Cosmai, L. et al. Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies. ESMO Open 5, 1–8 (2020).
138. Conteduca, V. et al. Immune modulation in prostate cancer patients treated with androgen receptor (Ar)-targeted therapy. J. Clin. Med. 9, 1 (2020).
139. Claps, M. et al. Current Understanding of Urachal Adenocarcinoma and Management Strategy. Curr. Oncol. Rep. 22, (2020).
140. Claps, M. et al. Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes. Cancer Treat. Rev. 88, (2020).
141. Cappelletti, V. et al. Analysis of single circulating tumor cells in renal cell carcinoma reveals phenotypic heterogeneity and genomic alterations related to progression. Int. J. Mol. Sci. 21, (2020).
142. Cagnazzo, C. et al. Phase I studies: a test bench for Italian clinical research. Tumori 106, 295–300 (2020).
143. Caffo, O. et al. On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2. Ann. Oncol. 31, 1415–1416 (2020).
144. Caffo, O. et al. Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer. Eur. J. Cancer 140, 140–146 (2020).
145. Buti, S. et al. Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study. Cancer. Treat. Res. Commun 22, (2020).
146. Brunelli, C. et al. PATIENT VOICES, a project for the integration of the systematic assessment of patient reported outcomes and experiences within a comprehensive cancer center: A protocol for a mixed method feasibility study. Health Qual. Life Outcomes 18, (2020).
147. Bersanelli, M. et al. Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study. Immunother. 12, 151–159 (2020).
148. Antonarakis, E. S. et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study. in J. Clin. Oncol. vol. 38 395–405 (American Society of Clinical Oncology, 2020).

149. Verzoni, E. et al. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program. J. Immunother. Cancer 7, (2019).
150. Sepe, P. et al. Could circulating tumor cells and ARV7 detection improve clinical decisions in metastatic castration-resistant prostate cancer? The istituto nazionale dei tumori (INT) experience. Cancers 11, (2019).
151. Schmidinger, M. et al. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). Oncologist 24, 491–497 (2019).
152. Sartor, O. et al. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases. Prostate 79, 1683–1691 (2019).
153. Raimondi, A., Sepe, P., Claps, M., Verzoni, E. & Procopio, G. Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma? Expert Opin. Biol. Ther. 19, 1107–1110 (2019).
154. Raimondi, A. et al. The evaluation of response to immunotherapy in metastatic renal cell carcinoma: Open challenges in the clinical practice. Int. J. Mol. Sci. 20, (2019).
155. **Procopio, G.**, Sepe, P., Claps, M., de Braud, F. & Verzoni, E. Should we use combination therapy for all advanced renal cell carcinoma? Lancet Oncol. 20, 1331–1332 (2019).
156. **Procopio, G.** et al. Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: A position paper of the MeetURO Group. Future Oncol. 15, 2657–2666 (2019).
157. **Procopio, G.** et al. Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. Clin. Genitourin. Cancer 17, e526–e533 (2019).
158. **Procopio, G.** et al. Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. Eur Urol Oncol 2, 699–707 (2019).
159. Prisciandaro, M. et al. Safety and efficacy of cabozantinib for metastatic nonclear renal cell carcinoma: Real-world data from an Italian managed access program. Am. J. Clin. Oncol. Cancer Clin. Trials 42, 42–45 (2019).
160. Peverelli, G. et al. Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. Clin. Genitourin. Cancer 17, 291–298 (2019).
161. Pagani, F. et al. Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives. Cancer Treat. Rev. 79, (2019).
162. Masini, C. et al. Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study. Clin. Genitourin. Cancer 17, e150–e155 (2019).
163. Giuseppa Vitale, M. et al. Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). Tumori 105, 3–12 (2019).
164. De Giorgi, U. et al. Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab. Clin. Cancer Res. 25, 3839–3846 (2019).
165. De Giorgi, U. et al. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. BJU Int. 123, 98–105 (2019).
166. Capasso, A. et al. Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. Kidney Int. 96, 555–567 (2019).
167. Banna, G. L. et al. Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica. Crit. Rev. Oncol. Hematol. 137, 154–164 (2019).
168. Apollonio, G. et al. The role of metastasectomy in advanced renal cell carcinoma. Expert Rev. Anticancer Ther. 19, 603–

611 (2019).

169. Vitale, M. G. et al. Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab expanded access program (EAP) in Italy. PLoS ONE 13, (2018).
170. Verzoni, E. et al. TARIBO trial: Targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: Liquid biopsy for biomarkers discovery. Tumori 104, 401–405 (2018).
171. Ratta, R. et al. Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis. Clin. Genitourin. Cancer 16, e735–e742 (2018).
172. **Procopio, G.**, Sepe, P., Verzoni, E., Pignata, S. & Bamias, A. Adjuvant treatment of high-risk renal cell carcinoma: The jury is still out. Ann. Oncol. 29, 2030–2032 (2018).
173. **Procopio, G.**, Ratta, R., de Braud, F. & Verzoni, E. Combination therapies for patients with metastatic renal cell carcinoma. Lancet Oncol. 19, 281–283 (2018).
174. **Procopio, G.** et al. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. Clin. Genitourin. Cancer 16, e945–e951 (2018).
175. Mennitto, A., Verzoni, E., Peverelli, G., Alessi, A. & Procopio, G. Management of Metastatic Collecting Duct Carcinoma: An Encouraging Result in a Patient Treated With Cabozantinib. Clin. Genitourin. Cancer 16, e521–e523 (2018).
176. Maines, F. et al. Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: The Italian Named Patient Program. Future Oncol. 14, 2691–2699 (2018).
177. De Gobbi, A. et al. Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: Single institute experience. Tumori 104, 388–393 (2018).
178. Bracarda, S. et al. Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program. Future Oncol. 14, 1347–1354 (2018).
179. Bersanelli, M. et al. INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDIa study. Immunother. 10, 1229–1239 (2018).
180. Akaza, H. et al. Metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy: Treatment patterns from the PRoxima prospective registry. J. Glob. Oncol. 2018, 1–12 (2018).
181. Sartor, O. et al. Re-treatment with radium-223: First experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. Ann. Oncol. 28, 2464–2471 (2017).
182. Santini, D. et al. Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: A multicenter retrospective analysis. Oncotarget 8, 100708–100716 (2017).
183. Ratta, R., Prisciandaro, M. & Procopio, G. Personalized therapy in renal cell carcinoma: Are the different tyrosine kinase inhibitors the same for any patient? Expert Rev. Precis. Med. Drug Dev. 2, 5–7 (2017).
184. Ratta, R., Grassi, P., Fucà, G., Verzoni, E. & Procopio, G. Castration-naive metastatic prostate cancer: reshaping old paradigms. Expert Rev. Anticancer Ther. 17, 879–881 (2017).
185. Pusceddu, S. et al. Everolimus treatment for neuroendocrine tumors: Latest results and clinical potential. Ther. Adv. Med. Oncol. 9, 183–188 (2017).
186. Mennitto, A. et al. Multimodal treatment of advanced renal cancer in 2017. Expert Rev. Clin. Pharmacol. 10, 1395–1402 (2017).
187. Mennitto, A., Grassi, P., Verzoni, E., Ratta, R. & Procopio, G. Does F-18 FDG-PET still play a role in metastatic renal cell carcinoma? J. Med. Imaging Radiat. Oncol. 61, 250–251 (2017).
188. Mennito, A., Verzoni, E., Calareso, G., Spreafico, C. & Procopio, G. Treatment of advanced renal cell carcinoma: Recent advances and current role of immunotherapy, surgery, and cryotherapy. Tumori 103, 15–21 (2017).

189. Grassi, P. et al. Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma? Drugs R D 17, 461–467 (2017).
190. Grassi, P. et al. Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents. Oncology 92, 269–275 (2017).
191. Escudier, B. et al. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma [Figure presented]. Eur. Urol. 72, 962–971 (2017).
192. Elgendy, M. et al. Dual modulation of MCL-1 and mTOR determines the response to sunitinib. J. Clin. Invest. 127, 153–168 (2017).
193. Baldari, S. et al. Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel. Crit. Rev. Oncol. Hematol. 113, 43–51 (2017).
194. Zanardi, E. et al. Treatment of elderly patients with metastatic renal cell carcinoma. Expert Rev. Anticancer Ther. 16, 323–334 (2016).
195. Verzoni, E. et al. Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. Ther. Adv. Med. Oncol. 8, 323–330 (2016).
196. Verzoni, E. et al. Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: A retrospective cohort study. Oncotarget 7, 40085–40094 (2016).
197. Veccia, A. et al. Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. Future Oncol. 12, 493–502 (2016).
198. Santini, D. et al. Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. Oncotarget 7, 33381–33390 (2016).
199. Ratta, R. et al. Immunotherapy advances in uro-genital malignancies. Crit. Rev. Oncol. Hematol. 105, 52–64 (2016).
200. **Procopio, G.**, Ratta, R. & Grassi, P. Evolving treatment landscape in metastatic renal cell carcinoma: Where are we now? Expert Rev. Anticancer Ther. 16, 133–135 (2016).
201. **Procopio, G.**, Ratta, R. & de Braud, F. Improved quality of life is the way to longer life. Lancet Oncol. 17, 862–863 (2016).
202. Necchi, A. et al. An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. in Invest. New Drugs vol. 34 236–242 (Springer New York LLC, 2016).
203. Mennitto, A., Vernieri, C. & Procopio, G. Urachal carcinoma: Towards a precision medicine. Transl. Cancer Res. 5, S1307–S1310 (2016).
204. Mennitto, A. et al. Nivolumab in the treatment of advanced renal cell carcinoma: Clinical trial evidence and experience. Ther. Adv. Urol. 8, 319–326 (2016).
205. Maines, F. et al. Safety and Clinical Outcomes of Abiraterone Acetate after Docetaxel in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. Clin. Genitourin. Cancer 14, 48–55 (2016).
206. Magnani, T. et al. Multidisciplinary approach of prostate cancer patients. in Bone Metastases from Prostate Cancer: Biology, Diagnosis and Management 281–293 (Springer International Publishing, 2016). doi:10.1007/978-3-319-42327-2_21.
207. Grassi, P. et al. Cabozantinib in the treatment of advanced renal cell carcinoma: Design, development, and potential place in the therapy. Drug Des. Dev. Ther. 10, 2167–2172 (2016).
208. Grassi, P., Verzoni, E. & Procopio, G. Adjuvant treatment for renal cell carcinoma: in the long run will we get the same answers? Expert Rev. Anticancer Ther. 16, 803–804 (2016).
209. Grassi, P., Verzoni, E., Mennitto, A. & Procopio, G. Cabozantinib in advanced renal cell carcinoma: A METEOR impact on

clinical practice. Transl. Androl. Urol. 5, 974–976 (2016).

210. Grassi, P. et al. Clinical impact of Pancreatic metastases from renal cell carcinoma: A multicenter retrospective analysis. PLoS ONE 11, (2016).
211. Fiorentini, C. et al. Antisecretive and antitumor activity of abiraterone acetate in human adrenocortical cancer: A preclinical study. J. Clin. Endocrinol. Metab. 101, 4594–4602 (2016).
212. Zanardi, E. et al. Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma. Ther. Adv. Urol. 7, 152–161 (2015).
213. Verzoni, E. et al. TOKIO rationale and protocol: A phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma. Tumori 101, 701–703 (2015).
214. Santoni, M. et al. Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? J. Exp. Clin. Cancer Res. 34, (2015).
215. Santoni, M. et al. Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. J. Urol. 193, 41–47 (2015).
216. Santoni, M. et al. Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. Ann. Surg. Oncol. 22, 2094–2100 (2015).
217. Santoni, M. et al. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials. Int. J. Cancer 136, 1–10 (2015).
218. Santoni, M. et al. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Targeted Oncol. 10, 517–522 (2015).
219. Ratta, R., Verzoni, E., Grassi, P., Niger, M. & Procopio, G. Predicting Molecular Models: Where Are We Going? EBioMedicine 2, 1594–1595 (2015).
220. Raggi, D. et al. Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. Urol. Oncol. Semin. Orig. Invest. 33, 332.e19-332.e24 (2015).
221. Pusceddu, S., Indini, A. & Procopio, G. Everolimus treatment in advanced solid tumors: A personal view. Futur. Sci. OA 1, (2015).
222. **Procopio, G.** et al. Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: Overall results from a large cohort of patients. Oncology 88, 133–138 (2015).
223. **Procopio, G.** et al. Safety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factors. Am. J. Clin. Oncol. Cancer Clin. Trials 38, 479–482 (2015).
224. Pantano, F. et al. The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: A new pharmacodynamic marker? PLoS ONE 10, (2015).
225. Necchi, A. et al. Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective from a Referral Center. Clin. Genitourin. Cancer 13, 385-391.e1 (2015).
226. Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. New Engl. J. Med. 373, 1803–1813 (2015).
227. Iacovelli, R. et al. Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: A systematic review and meta-analysis. Curr. Drug Targets 16, 164–170 (2015).
228. Iacovelli, R. et al. Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data. Clin. Genitourin. Cancer 13, 137–141 (2015).
229. Iacovelli, R. et al. Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with

metastatic renal cell carcinoma. J. Can. Urol. Assoc. 9, 263–267 (2015).

230. Iacovelli, R. et al. Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma. J. Urol. 193, 1905–1910 (2015).

231. Grassi, P. et al. Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib. Ther. Adv. Urol. 7, 59–68 (2015).

232. Conteduca, V. et al. Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. Future Oncol. 11, 2881–2891 (2015).

233. Caffo, O. et al. Clinical outcomes in a contemporary series of 'young' patients with castration-resistant prostate cancer who were 60 years and younger. Urol. Oncol. 33, 265.e15–21 (2015).

234. Caffo, O. et al. Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: Results of the Italian Named Patient Programme. BJU Int. 115, 764–771 (2015).

235. Caffo, O. et al. Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: Results of an Italian multicentre study. Eur. Urol. 68, 147–153 (2015).

236. Bracarda, S. et al. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis. Ann. Oncol. 26, 2107–2113 (2015).

237. Verzoni, E. et al. Safety profile and treatment response of everolimus in different solid tumors: An observational study. Future Oncol. 10, 1611–1617 (2014).

238. Verzoni, E. et al. Targeted treatments in advanced renal cell carcinoma: Focus on Axitinib. Pharm. Person. Med. 7, 107–116 (2014).

239. Testa, I. et al. Response to targeted therapy in urachal adenocarcinoma. Rare Tumors 6, 124–127 (2014).

240. Pusceddu, S., Tessari, A., Testa, I. & Procopio, G. Everolimus in advanced solid tumors: When to start, early or late. Tumori 100, e2–e3 (2014).

241. **Procopio, G.**, Verzoni, E. & De Braud, F. Butterfly and renal cell cancer: Out of chaos comes order. J. Clin. Oncol. 32, 3083 (2014).

242. **Procopio, G.** et al. Rationale and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical resection of the metastases. Tumori 100, e28–e30 (2014).

243. **Procopio, G.** et al. Treatment of collecting duct carcinoma: Current status and future perspectives. Anticancer Res. 34, 1027–1030 (2014).

244. **Procopio, G.** et al. Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. Future Oncol. 10, 1741–1750 (2014).

245. Iacovelli, R. et al. Rationale and protocol of SOAP: A phase II study to evaluate the efficacy of Sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma. Tumori 100, e282–e285 (2014).

246. Iacovelli, R., Verzoni, E., De Braud, F. M. & Procopio, G. Study design and clinical evidence in mRCC: Can we save axitinib as a first-line therapy? Cancer Biol. Ther. 15, 486–488 (2014).

247. Iacovelli, R., Verzoni, E., De Braud, F. & Procopio, G. First line treatment of metastatic renal cell carcinoma: Two standards with different toxicity profile. Cancer Biol. Ther. 15, 19–21 (2014).

248. Iacovelli, R., Santoni, M., De Braud, F., Cascinu, S. & Procopio, G. Highlights from the ASCO Genitourinary Symposium 2014: Focus on renal and prostate cancer. in Expert Rev. Anticancer Ther. vol. 14 1407–1409 (Expert Reviews Ltd., 2014).

249. Iacovelli, R. et al. Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase

inhibitors for malignancy. Br. J. Clin. Pharmacol. 77, 929–938 (2014).

250. Iacovelli, R. et al. Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib. Can. Urol. Assoc. J. 8, e121–e125 (2014).

251. Grassi, P. et al. Targeted therapies in advanced renal cell carcinoma: The role of metastatic sites as a prognostic factor. Future Oncol. 10, 1361–1372 (2014).

252. Cremona, M. et al. Stratification of clear cell renal cell carcinoma by signaling pathway analysis. Expert Rev. Proteomics 11, 237–249 (2014).

253. Bracarda, S. et al. Real-world cabazitaxel safety: The Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncol. 10, 975–983 (2014).

254. Bracarda, S. et al. Axitinib safety in metastatic renal cell carcinoma: Suggestions for daily clinical practice based on case studies. Expert Opin. Drug Saf. 13, 497–510 (2014).

255. Biondani, P. et al. Sequential tyrosine kinase inhibitors (TKIs) in metastatic renal cell carcinoma: Results from a large cohort of patients. Anticancer Res. 34, 2395–2398 (2014).

256. Verzoni, E., Garanzini, E. & Procopio, G. Complete responses in advanced renal cell carcinoma: Utopia or real chance? Clin. Exp. Nephrol. 17, 151–152 (2013).

257. Verzoni, E. et al. Patient approach in advanced/metastatic renal cell carcinoma: Focus on the elderly population and treatment-related toxicity. Future Oncol. 9, 1599–1607 (2013).

258. Santini, D. et al. Natural history of malignant bone disease in renal cancer: Final results of an italian bone metastasis survey. PLoS ONE 8, (2013).

259. Sabbatini, R. et al. Metastatic renal cell carcinoma: How to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor. Future Oncol. 9, 831–843 (2013).

260. **Procopio, G.** et al. Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): Final results of the ROSORC trial. Ann. Oncol. 24, 2967–2971 (2013).

261. **Procopio, G.** et al. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: Results from a large pooled analysis. Br. J. Cancer 108, 311–318 (2013).

262. Paglino, C. et al. A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer. Anticancer Res. 33, 4999–5004 (2013).

263. Iacovelli, R. et al. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. Eur. J. Cancer 49, 2134–2142 (2013).

264. Iacovelli, R. et al. Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials. Prostate Cancer Prostatic Dis. 16, 323–327 (2013).

265. Grassi, P. et al. Prognostic role of pancreatic metastases from renal cell carcinoma: Results from an Italian center. Clin. Genitourin. Cancer 11, 484–488 (2013).

266. Bellardita, L. et al. Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance. Eur. Urol. 64, 30–36 (2013).

267. Verzoni, E., Lanocita, R. & Procopio, G. Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: A case report. Clin. Genitourin. Cancer 10, 130–133 (2012).

268. Testa, I., Verzoni, E., Catanzaro, M., Biasoni, D. & Procopio, G. Castration resistant prostate cancer: The activity of non chemotherapeutic agents in Adenocarcinoma: Pathogenesis, Treat. and Prognosis 157–174 (Nova Science Publishers, Inc., 2012).

269. **Procopio, G.** et al. Experience with sorafenib in the treatment of advanced renal cell carcinoma. Ther. Adv. Urol. 4, 303–

313 (2012).

270. **Procopio, G.** et al. Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. Br. J. Cancer 107, 1227–1232 (2012).
271. **Procopio, G.** et al. Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. Clin. Exp. Nephrol. 16, 464–467 (2012).
272. **Procopio, G.**, Verzoni, E. & De Braud, F. Targeted therapies and survival: What we can learn from studies in advanced renal cell carcinoma. Oncology 84, 39–42 (2012).
273. **Procopio, G.**, Verzoni, E. & De Braud, F. Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: An exploratory analysis of the outcomes of elderly patients in the RECORD-1 trial. Eur Urol 2012;61:826-33. Eur. Urol. 62, e5 (2012).
274. **Procopio, G.** et al. Optimizing further treatment choices in short-and long-term responders to first-line therapy for patients with advanced renal cell carcinoma. Expert Rev. Anticancer Ther. 12, 1089–1096 (2012).
275. **Procopio, G.**, Pusceddu, S. & Buzzoni, R. Sunitinib and everolimus in pancreatic neuroendocrine tumors. Tumori 98, 394 (2012).
276. Porta, C. et al. Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: State-of-the-science. Expert Rev. Anticancer Ther. 12, 1571–1577 (2012).
277. Pietrantonio, F., Biondani, P., Verzoni, E. & Procopio, G. Management of advanced genitourinary tumors. in Tumori vol. 98 264–266 (Il Pensiero Scientifico Editore s.r.l., 2012).
278. Masini, C. et al. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: A retrospective Italian survey. BJU Int. 110, 692–698 (2012).
279. Magnani, T. et al. The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy: Incidence of management changes. BJU Int. 110, 998–1003 (2012).
280. Iacovelli, R., Palazzo, A., Procopio, G., Gazzaniga, P. & Cortesi, E. Abiraterone acetate in castration-resistant prostate cancer. Anti-Cancer Drugs 23, 247–254 (2012).
281. Biondani, P., Procopio, G., Pietrantonio, F., De Braud, F. & Verzoni, E. New perspectives in advanced genitourinary malignancies. in Tumori vol. 98 267–269 (2012).
282. Altavilla, A., Iacovelli, R., Procopio, G. & Cortesi, E. Post-docetaxel therapy in castration resistant prostate cancer – the forest is growing in the desert. Ther. Adv. Urol. 4, 107–111 (2012).
283. Altavilla, A. et al. Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. Cancer Biol. Ther. 13, 1001–1008 (2012).
284. Pusceddu, S., Milione, M. & Procopio, G. Compassionate use of everolimus in a patient with a neuroendocrine tumor: A case report and discussion of the literature. Oncol. Res. 19, 403–406 (2011).
285. **Procopio, G.** et al. Targeted therapies used sequentially in metastatic renal cell cancer: Overall results from a large experience. Expert Rev. Anticancer Ther. 11, 1631–1640 (2011).
286. **Procopio, G.** et al. Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: The ROSORC trial. Br. J. Cancer 104, 1256–1261 (2011).
287. **Procopio, G.**, Niger, M. & Testa, I. Lecture: management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors. Neurol. Sci. 32 Suppl 2, S217-219 (2011).
288. **Procopio, G.** et al. Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. BJU Int. 108, 223–227 (2011).
289. **Procopio, G.**, Giganti, M. O., Guadalupi, V., Testa, I. & Verzoni, E. REPLY. BJU Int. 107, 1327 (2011).

290. **Procopio, G.** Role of sorafenib in renal cell carcinoma: Focus on elderly patients. Expert Rev. Anticancer Ther. 11, 1689–1692 (2011).
291. Porta, C. et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): An Italian multicentre retrospective analysis of 189 patient cases. BJU Int. 108, E250–E257 (2011).
292. Mazzola, R., Alù, M., Leonardi, V., Procopio, G. & Agostara, B. Capecitabine in combination with oxaliplatin as first-line therapy for advanced gastric cancer: A case report. Tumori 97, 115–118 (2011).
293. Beck, J. et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: A large open-label study in diverse community settings. Ann. Oncol. 22, 1812–1823 (2011).
294. **Procopio, G.**, Verzoni, E., Guadalupi, V., Iacovelli, R. & Bajetta, E. Is it possible to optimize the use of targeted therapies in the treatment of renal cell carcinoma? Tumori 96, 794–795 (2010).
295. **Procopio, G.**, Verzoni, E. & Bajetta, E. Feasibility and activity for sequencing targeted therapies for the treatment of advanced renal cell carcinoma. Med. Oncol. 27, 1267–1268 (2010).
296. **Procopio, G.** et al. Prostate cancer in the elderly: Which therapy? Geriatr. Med. Intell. 19, 52–57 (2010).
297. Mickisch, G. et al. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: Bevacizumab in combination with interferon-α2a compared with sunitinib. Br. J. Cancer 102, 80–86 (2010).
298. Mickisch, G. et al. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: Bevacizumab in combination with interferon-α2a compared with sunitinib. J. Urol. 184, 1303–1304 (2010).
299. Iacovelli, R., Raimondi, C., Palazzo, A., Cortesi, E. & Procopio, G. Neoadjuvant targeted therapy in renal cell carcinoma. Nat. Rev. Urol. 7, (2010).
300. **Procopio, G.**, Verzoni, E., Guadalupi, V. & Bajetta, E. Sorafenib in the treatment of elderly patients affected by advanced Renal Cell Cancer (RCC). Geriatr. Med. Intell. 18, 125–130 (2009).
301. Bajetta, E. et al. From biology to clinical experience: Evolution in the knowledge of neuroendocrine tumours. Oncology Rev. 3, 79–87 (2009).
302. Bajetta, E., Procopio, G., Guadalupi, V. & Del Vecchio, M. Letter to the editor. Clin. Ther. 31, 2060–2061 (2009).
303. Bajetta, E., Guadalupi, V. & Procopio, G. Activity of sunitinib in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 27, 319–320 (2009).
304. Bajetta, E. et al. Pitfalls in the diagnosis of neuroendocrine tumors: Atypical clinical and radiological findings as cause of medical mistakes. Tumori 95, 501–507 (2009).
305. **Procopio, G.** et al. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. Oncology (Switzerland) 73, 204–209 (2008).
306. De Dosso, S. et al. Pulmonary carcinoid tumours: Indolent but not benign. Oncology (Switzerland) 73, 162–168 (2008).
307. Bajetta, E. et al. Renal cell cancer and sorafenib: Skin toxicity and treatment outcome. Tumori 93, 201–203 (2007).
308. Bajetta, E. et al. Merkel cell carcinoma after liver transplantation: A case report. Tumori 93, 323–326 (2007).
309. Bajetta, E. et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother. Pharmacol. 59, 637–642 (2007).
310. **Procopio, G.** et al. Neuroendocrine tumors of the larynx: A clinical report and literature review. Tumori 92, 72–75 (2006).
311. Ferrari, L. et al. Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumors. Tumori 92, 531–535 (2006).
312. Bajetta, E. et al. Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: A phase III study. Cancer 107, 2474–2481 (2006).
313. Valdagni, R. et al. In regard to Kagan: 'The multidisciplinary clinic' (Int J Radiat Oncol Biol Phys 2005;61:967-968) [3]. Int. J.

Radiat. Oncol. Biol. Phys. 63, 309–310 (2005).

314. Bajetta, E. et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J. Clin. Oncol. 23, 2155–2161 (2005).
315. Bajetta, E. et al. Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment? Ann. Oncol. 16, 1374–1380 (2005).
316. Fusi, A. et al. Treatment options in hormone-refractory metastatic prostate carcinoma. Tumori 90, 535–546 (2004).
317. Ferrari, L. et al. Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors. Int. J. Biol. Markers 19, 295–304 (2004).
318. Gattinoni, L. et al. Renal cancer treatment: A review of the literature. Tumori 89, 476–484 (2003).
319. Della Torre, S. et al. Current treatments of neuroendocrine tumors role of biotherapy and chemotherapy. Tumori 89, 111–116 (2003).
320. Bajetta, E. et al. Update on the treatment of neuroendocrine tumors. Expert Rev. Anticancer Ther. 3, 631–642 (2003).
321. Bajetta, E. et al. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer 94, 299–304 (2002).
322. Bajetta, E. et al. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann. Oncol. 13, 614–621 (2002).
323. Cassata, A. et al. Capecitabine: Indications and future perspectives in the treatment of metastatic colorectal and breast cancer. Tumori 87, 364–371 (2001).
324. Bombardieri, E. et al. Radioisotopic imaging of neuroendocrine tumours. Which radiopharmaceutical and which diagnostic procedure? Minerva Endocrinol. 26, 197–213 (2001).
325. Bajetta, E. et al. Advances in diagnosis and therapy of neuroendocrine tumors. Expert Rev. Anticancer Ther. 1, 371–381 (2001).
326. Bajetta, E. et al. Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma A phase II trial. Cancer 89, 763–768 (2000).
327. Del Vecchio, M. et al. Fluoropyrimidines in the treatment of advanced neoplastic diseases: Role and advantages of UFT. Tumori 85, 6–11 (1999).
328. Celio, L. et al. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study. Anticancer Res. 19, 2261–2268 (1999).
329. Bajetta, E. et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 86, 858–865 (1999).
330. Bajetta, E. et al. 5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 83, 372–378 (1998).

Aggiornamento al 14/04/2025, dati Scopus, oltre 14 mila citazioni, H/INDEX 46

Milano, 14/04/2025